Sugi Predict

Sugi Predict / Compounds / SCHEMBL2457673

SCHEMBL2457673

SCHEMBL2457673

N[N+]12C=CN=CC1=C(C1CC(OCC(=O)[O-])C1)N=C2c1cccc(OCc2ccccc2)c1

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 4/20 0.37
▸ MRGPRX4 Q96LA9 1/20 0.36
▸ IGF1R P08069 2/20 0.35
▸ NAAA Q02083 2/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ TNK2 Q07912 1/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ NR4A2 P43354 1/20 0.34
▸ PTGIR P43119 4/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ NR1H4 Q96RI1 1/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459807 0.86 IGF1R (0.47) DHODHMRGPRX4IGF1RHDAC4TNK2
SCHEMBL2460636 0.86 IGF1R (0.39) MRGPRX4IGF1RTNK2
SCHEMBL2463550 0.85 DHODH (0.33) DHODHMRGPRX4IGF1RHDAC4TNK2
SCHEMBL2460659 0.85 IGF1R (0.47) IGF1RTNK2
SCHEMBL2459711 0.84 IGF1R (0.41) IGF1RTNK2
SCHEMBL2460065 0.84 IGF1R (0.36) IGF1RNAAATNK2
SCHEMBL2458683 0.84 IGF1R (0.37) MRGPRX4IGF1RTNK2
SCHEMBL2457374 0.83 IGF1R (0.43) MRGPRX4IGF1RTNK2JAK2JAK1
SCHEMBL2457535 0.83 IGF1R (0.38) IGF1RTNK2
SCHEMBL2460551 0.82 IGF1R (0.48) MRGPRX4IGF1RJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 DHODH 3525/4885MRGPRX4 1767/4885IGF1R 1/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 DHODH 3525/4885MRGPRX4 1767/4885IGF1R 1/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 DHODH 3525/4885MRGPRX4 1767/4885IGF1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.